SLGG yields 2336.45% · ABBV yields 3.06%● Live data
📍 SLGG pulled ahead of the other in Year 1
Combined, SLGG + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SLGG + ABBV for your $10,000?
Super League Gaming, Inc. builds and operates networks of games, monetization tools, and content channels across metaverse gaming platforms that empower developers, energize players, and entertain fans. The company's solutions provide access to an audience consisting of players in the metaverse environments, fans of various gaming influencers, and viewers of gameplay content across social media and digital video platforms. The company's platform includes access to in-game communities, a metaverse advertising platform, and a network of highly viewed channels and original shows on Instagram, TikTok, Snap, YouTube, and Twitch, as well as cloud-based livestream production tools and an esports invitational tournament series. Its properties also deliver opportunities for brands and advertisers to achieve insights and marketing outcomes with gamers of various ages. The company was formerly known as Nth Games, Inc. and changed its name to Super League Gaming, Inc. in June 2015. The company was incorporated in 2014 and is headquartered in Santa Monica, California.
Full SLGG Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.